Pfizer News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

13.09.13	GlycoMimetics' GMI-1070 Granted Orphan Drug Designation In EU - Quick Facts (RTTNews)
13.09.13	ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naive Adults with HIV-1 (PR Newswire)
09.09.13	Event, FDA Approval, Positive Results, Partnership, and Marketing Authorization - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Lilly, and GSK (PR Newswire)
06.09.13	Critical Alerts For FedEx, AmerisourceBergen, Yelp, Pfizer, and Monsanto Released By InvestorsObserver (PR Newswire)
03.09.13	BMY, Pfizer Records Consistent Results In Sub-analysis Of Eliquis Vs. Warfarin (RTTNews)
31.08.13	Bristol-Myers,Pfizer Report Results Of Post-hoc Subanalysis From ARISTOTLE Trial (RTTNews)
29.08.13	Early Briefing and Review: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc. (PR Newswire)
29.08.13	Pfizer Closes Pneumococcal Pneumonia Case Accrual For CAPiTA - Quick Facts (RTTNews)
19.08.13	MNKD To Get Financing, PTIE, DRRX Vault, BMRN On Watch (RTTNews)
13.08.13	UPDATE: Multimedia Assets Now Available: ViiV Healthcare announces U.S. approval of Tivicay® (dolutegravir) for the treatment of HIV-1 (PR Newswire)
13.08.13	ViiV Healthcare Says FDA Approves HIV Drug Tivicay (RTTNews)
13.08.13	ViiV Healthcare Announces FDA Approves Tivicay For HIV-1 Treatment - Quick Facts (RTTNews)
13.08.13	ViiV Healthcare announces U.S. approval of Tivicay® (dolutegravir) for the treatment of HIV-1 (PR Newswire)
06.08.13	Positive Opinions, Solid Margins, Agreements, and Clinical Trials to Boost Run Rate of Drug Manufacturers - Research Report on Johnson & Johnson, Pfizer, Merck, Bristol-Myers Squibb, and Lilly (PR Newswire)
05.08.13	Short Interest Activity for Today's Leaders with Bullish Growth Trends - GRILLiT, Sirius, Pfizer, Nokia, Intel (PR Newswire)
31.07.13	Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint (PR Newswire)
30.07.13	Pfizer Profit Surges On Zoetis Spinoff, Patent Settlement Gains; Backs Forecast (RTTNews)
29.07.13	Pfizer To Internally Separate Its Branded, Generic Businesses - Update (RTTNews)
29.07.13	Pfizer Plans To Internally Separate Commercial Operations Into Three Segments (RTTNews)
25.07.13	CHMP Confirms Prior Opinion Regarding Marketing Authorization in Europe for Pfizer’s XELJANZ® (tofacitinib citrate) (Businesswire)
24.07.13	Technical Briefing: Pfizer, Merck & Co., AbbVie, and Zogenix (PR Newswire)
24.07.13	Mylan Reaches Tarceva Settlement Agreement With OSI, Pfizer And Genentech (RTTNews)
23.07.13	Drug Approvals, Study Results, and Clinical Collaborations for Top-Line Growth - Research Report on Pfizer, Merck & Co., Cubist, AstraZeneca and Impax (PR Newswire)
17.07.13	Reports: Pfizer, Amgen Among Five Potential Suitors For Onyx (RTTNews)
15.07.13	Pfizer Provides Update On Global Regulatory Approvals For Tofacitinib (RTTNews)
11.07.13	RMTI Cruises Ahead, ALNY, CELG Touch New Highs, BIOD Progresses (RTTNews)
11.07.13	FDA Accepts Eliquis SNDA For Review - Quick Facts (RTTNews)
10.07.13	Nu Skin Glows, It's Smile Time For CRY, INO Making Big Moves, PCYC On Watch (RTTNews)
10.07.13	Pfizer's Pneumococcal Vaccine Prevenar 13 Gets EU Nod For Expanded Use (RTTNews)
10.07.13	EU OKs Pfizer To Expand Use Of Prevenar 13 To Adults Aged 18-49 Yrs (RTTNews)
11.10.12	Pfizer Announces Top-Line Results From A Phase 3 Long-Term Safety Study Of ALO-02: (Businesswire)
10.10.12	New Report Reveals Programs That Promote Healthy Ageing Can Help Reduce Rising Health Costs1 (Businesswire)
21.09.12	ELIQUIS® (apixaban) Receives CHMP Positive Opinion For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation (Businesswire)
21.09.12	ELIQUIS® (apixaban) Receives CHMP Positive Opinion For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation (Businesswire)
04.09.12	Pfizer Receives EU Marketing Authorization for INLYTA® (Axitinib) (Businesswire)
15.08.12	Pfizer Commences Consent Solicitation for Amendments to Pharmacia Indentures (Businesswire)
10.08.12	Pfizer Reports Results From Phase 3 Study Of Torisel (temsirolimus) In Combination With Bevacizumab In Advanced Renal Cell Carcinoma (RCC) (Businesswire)
06.08.12	Summertime Shines a Light on the Need for Vitamin D (Businesswire)
31.07.12	Pfizer Reports Second-Quarter 2012 Results (Businesswire)
19.07.12	Pfizer and Northwestern University Win LYRICA® Patent Case in Delaware District Court (Businesswire)
28.06.12	Pfizer Declares A 22-Cent Third-Quarter 2012 Dividend (Businesswire)
26.06.12	Pfizer Invites Public to View and Listen to Webcast of July 31 Conference Call with Analysts (Businesswire)
21.06.12	FDA Approves Lyrica For The Management Of Neuropathic Pain Associated With Spinal Cord Injury Based On Priority Review (Businesswire)
20.06.12	Pfizer Statement Regarding Prevnar 13® Receiving ACIP Recommendation for Prevention of Pneumococcal Disease in Adults With Immunocompromising Conditions (Businesswire)
19.06.12	Pfizer Announces Positive Results From Phase 3 Study PROFILE 1007 Evaluating XALKORI® (crizotinib) In Previously Treated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (Businesswire)
18.06.12	FDA Issues Complete Response Letter For Pfizer’s Tafamidis Meglumine New Drug Application (Businesswire)
18.06.12	Have Americans Reached a New Era of Optimism about Aging? (Businesswire)
07.06.12	Pfizer Provides Update On Animal Health Strategic Alternatives Review Process (Businesswire)
25.05.12	Pfizer’s Axitinib Receives Positive Opinion from the Committee for Human Medicinal Products for the Second-line Treatment of Advanced Kidney Cancer in the EU (Businesswire)
23.05.12	Pfizer Names Olivier Brandicourt as President and General Manager, Emerging Markets and Established Products Business Units (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

16:16		EVOTEC-Aktie rutscht ab: Operatives Ergebnis mehr als halbiert
16:12		Roche-Aktie unbeeindruckt: Roche bringt neuen Test zur präziseren Leberfibrose-Diagnose auf den Markt
16:02		Dow Jones 30 Industrial-Wert Merck-Aktie: So viel Gewinn hätte ein Merck-Investment von vor 10 Jahren eingefahren
16:02		S&P 500-Papier Pfizer-Aktie: So viel hätten Anleger mit einem Investment in Pfizer von vor 10 Jahren verloren
10:02		EURO STOXX 50-Wert Sanofi-Aktie: So viel Verlust hätte eine Investition in Sanofi von vor 3 Jahren bedeutet
10:02		TecDAX-Papier EVOTEC SE-Aktie: So viel Verlust hätte ein Investment in EVOTEC SE von vor 3 Jahren bedeutet
05.05.25		DAX 40-Papier Merck-Aktie: So viel Verlust hätte eine Merck-Investition von vor einem Jahr eingebracht
05.05.25		SMI-Papier Novartis-Aktie: So viel Gewinn hätte ein Investment in Novartis von vor 10 Jahren abgeworfen

16:16

EVOTEC-Aktie rutscht ab: Operatives Ergebnis mehr als halbiert

16:12

Roche-Aktie unbeeindruckt: Roche bringt neuen Test zur präziseren Leberfibrose-Diagnose auf den Markt

16:02

Dow Jones 30 Industrial-Wert Merck-Aktie: So viel Gewinn hätte ein Merck-Investment von vor 10 Jahren eingefahren

16:02

S&P 500-Papier Pfizer-Aktie: So viel hätten Anleger mit einem Investment in Pfizer von vor 10 Jahren verloren

10:02

EURO STOXX 50-Wert Sanofi-Aktie: So viel Verlust hätte eine Investition in Sanofi von vor 3 Jahren bedeutet

10:02

TecDAX-Papier EVOTEC SE-Aktie: So viel Verlust hätte ein Investment in EVOTEC SE von vor 3 Jahren bedeutet

05.05.25

DAX 40-Papier Merck-Aktie: So viel Verlust hätte eine Merck-Investition von vor einem Jahr eingebracht

05.05.25

SMI-Papier Novartis-Aktie: So viel Gewinn hätte ein Investment in Novartis von vor 10 Jahren abgeworfen

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Swisscom	551.00	1.01 %	K V
Nestle	88.16	0.94 %	K V
Swiss Re	152.30	0.83 %	K V
Swiss Life Hldg	846.00	0.52 %	K V
Zurich Insur Gr	593.60	0.37 %	K V
Sonova Hldg	254.30	-1.20 %	K V
Alcon	79.64	-1.29 %	K V
Logitech Intl	63.44	-1.34 %	K V
ABB	44.69	-1.54 %	K V
Kuehne+Nagel Int	187.95	-2.08 %	K V

Pfizer Aktie VALOR 962004 / ISIN US7170811035

Nachrichten zu Pfizer Inc.

Aktien Top/Flop

Pfizer Peer Group Nachrichten

Meistgelesene Nachrichten